Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteNo recent work listed

Yasuhiko Tomita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2433-3788; OpenAlex author ID A5103207389. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers

Papers 9

  1. Imaging morphological changes of intraductal papillary mucinous neoplasm of the pancreas was associated with its malignant transformation but not with developm… Last author DOI 10.1016/j.pan.2015.08.004↗
  2. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Co-author DOI 10.1016/j.radonc.2015.01.004↗
  3. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000159↗
  4. Duodenal Hemorrhage from Pancreatic Cancer Infiltration Controlled through Combination Therapy with Gemcitabine and S-1. Co-author DOI 10.1159/000364819↗
  5. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy … Co-author DOI 10.1007/s00268-012-1775-x↗
  6. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including g… Last author DOI 10.1007/s00534-012-0514-x↗
  7. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based che… Co-author DOI 10.1097/sla.0b013e31823d813c↗
  8. Role of Meis1 in mitochondrial gene transcription of pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2011.06.066↗
  9. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Co-author DOI 10.1038/onc.2011.59↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroaki Ohigashi · 5 shared papers, 2011–2015 · strength 0.17
  2. Osamu Ishikawa · 5 shared papers, 2011–2015 · strength 0.17
  3. Hidenori Takahashi · 5 shared papers, 2011–2015 · strength 0.17
  4. Shigenori Nagata · 4 shared papers, 2011–2015 · strength 0.15
  5. Natsuko Kawada · 2 shared papers, 2012–2015 · strength 0.09
  6. Miki Tomoeda · 2 shared papers, 2011–2014 · strength 0.07
  7. Kazuhiro Katayama · 2 shared papers, 2012–2014 · strength 0.07
  8. Masahiro Tanemura · 2 shared papers, 2011–2014 · strength 0.07
  9. Masahiko Yano · 2 shared papers, 2012–2013 · strength 0.07
  10. Kunihito Gotoh · 2 shared papers, 2012–2013 · strength 0.07
  11. Yuichiro Doki · 2 shared papers, 2011–2012 · strength 0.05
  12. Hidetoshi Eguchi · 2 shared papers, 2011–2012 · strength 0.05
  13. Teruki Teshima · 1 shared paper, 2015 · strength 0.05
  14. Takero Hirata · 1 shared paper, 2015 · strength 0.05
  15. Kazuhiko Ogawa · 1 shared paper, 2015 · strength 0.05
  16. Keisuke Otani · 1 shared paper, 2015 · strength 0.05
  17. Koji Konishi · 1 shared paper, 2015 · strength 0.05
  18. Eiji Miyoshi · 1 shared paper, 2014 · strength 0.04
  19. Yoshihiro Kamada · 1 shared paper, 2014 · strength 0.04
  20. Nobuyasu Fukutake · 1 shared paper, 2014 · strength 0.04
  21. Tatsuya Ioka · 1 shared paper, 2014 · strength 0.04
  22. Takuo Yamai · 1 shared paper, 2014 · strength 0.04
  23. Ryoji Takada · 1 shared paper, 2014 · strength 0.04
  24. Reiko Ashida · 1 shared paper, 2014 · strength 0.04
  25. Hirotada Kittaka · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.